Banner - Telehealth Resources
Telehealth - Box Tabs
Telehealth resource - SAVINGS & SUPPORT
Savings & support
Injectafer savings & support
If you have an Injectafer prescription, you may be able to get help with your out-of-pocket costs.
Two ways to help you pay for Injectafer treatments‡
If Injectafer is covered by your commercial insurance, but you have a copay
If you’re eligible§, you may
- Receive assistance of up to $500 per dose with a maximum benefit of up to $1000 per course of treatment (2 doses)
- Stay enrolled for 2 courses of treatment (4 doses) per 12-month period
Doses are separated by at least 7 days.
For each course of treatment
Enroll in the savings program. On the enrollment form, provide your email address or mobile number to sign up for helpful infusion information, infusion reminders, and more.
§The Injectafer Savings Program is only available for adults 18 years or older who are commercially-insured or cash-paying patients. The program provides up to a maximum savings limit of $500 per dose and a maximum benefit of up to $1000 per course of treatment (2 doses). Enrollment is valid for 2 courses of therapy (4 doses). Insurance out of pocket must be over $50. Additional restrictions may apply. Please see full Terms and Conditions.
If you do not have insurance to cover treatment:
The Patient Assistance Program was created to help patients who lack health insurance and cannot afford therapy.
Call Daiichi Sankyo Access Central at 1-866-437-4669 to find out if you are eligible.
Terms and Conditions for the Injectafer Savings Program:
- This offer is valid for commercially-insured as well as cash paying patients.
- Depending on insurance coverage, eligible insured patients may pay no more than $50 for Injectafer for the first dose and $0 for Injectafer for the second dose, up to a maximum savings limit of $500 per dose, a $1,000 program limit per course of therapy. Check with your pharmacist or healthcare provider for your copay discount. Patient out-of-pocket expense may vary.
- This offer is not valid for patients enrolled in Medicare, Medicaid, or other federal or state healthcare programs, or private indemnity or HMO insurance plans that reimburse you for the entire cost of your prescription drugs. Patients may not use this card if they are Medicare-eligible and enrolled in an employer-sponsored health plan or medical or prescription drug benefit program for retirees.
- The offer is valid for 2 courses, or 4 doses, of an Injectafer prescription. An explanation of benefits statement must be faxed in prior to transacting on the account numbers for assistance. One enrollment is allowed per 12-month period.
- Daiichi Sankyo, Inc. reserves the right to rescind, revoke, or amend this offer without notice.
- Offer good only in the USA, including Puerto Rico, at participating pharmacies or healthcare providers.
- Void if prohibited by law, taxed, or restricted.
- This account number is not transferable. The selling, purchasing, trading, or counterfeiting of this account number is prohibited by law.
- This account number is not insurance.
- By redeeming this account number, you acknowledge that you are an eligible patient and that you understand and agree to comply with the terms and conditions of this offer.
- Qualified patients receiving Injectafer will be allowed a 60-day retroactive enrollment period to receive benefits under the program rules.
Eligibility requirements for the Patient Assistance Program:
To be eligible for the program, you must:
- Completely lack health insurance and be ineligible for public insurance or financing
- Be a US citizen, legal entrant in the United States, or permanent resident. Proof of citizenship or legal residency may also be required
- Meet income and other criteria
Providers (hospitals, physicians, or infusion centers) must apply to the program on behalf of their patients. They will need to fill out and fax the Patient Assistance Request form and Enrollment Application.
Important Safety Information
Injectafer® (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, or who have non-dialysis dependent chronic kidney disease.
IMPORTANT SAFETY INFORMATION
Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components.
WARNINGS AND PRECAUTIONS
Symptomatic hypophosphatemia requiring clinical intervention has been reported in patients at risk of low serum phosphate in the postmarketing setting. These cases have occurred mostly after repeated exposure to Injectafer in patients with no reported history of renal impairment. Possible risk factors for hypophosphatemia include a history of gastrointestinal disorders associated with malabsorption of fat-soluble vitamins or phosphate, concurrent or prior use of medications that affect proximal renal tubular function, hyperparathyroidism, vitamin D deficiency and malnutrition. In most cases, hypophosphatemia resolved within three months.
Monitor serum phosphate levels in patients at risk for low serum phosphate who require a repeat course of treatment.
Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions. In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1775) of these subjects.
In clinical studies, hypertension was reported in 3.8% (67/1775) of subjects. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1775) of subjects. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration.
In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer.
In two randomized clinical studies, a total of 1775 patients were exposed to Injectafer, 15 mg/kg of body weight, up to a single maximum dose of 750 mg of iron on two occasions, separated by at least 7 days, up to a cumulative dose of 1500 mg of iron. Adverse reactions reported by ≥2% of Injectafer-treated patients were nausea (7.2%); hypertension (3.8%); flushing/hot flush (3.6%); blood phosphorus decrease (2.1%); and dizziness (2.0%).
The following adverse reactions have been identified during post approval use of Injectafer. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been reported from the post-marketing spontaneous reports with Injectafer: cardiac disorders: tachycardia; general disorders and administration site conditions: chest discomfort, chills, pyrexia; metabolism and nutrition disorders: hypophosphatemia; musculoskeletal and connective tissue disorders: arthralgia, back pain, hypophosphatemic osteomalacia (rarely reported event); nervous system disorders: syncope; respiratory, thoracic and mediastinal disorders: dyspnea; skin and subcutaneous tissue disorders: angioedema, erythema, pruritus, urticaria.
CLINICAL CONSIDERATIONS IN PREGNANCY
Untreated IDA in pregnancy is associated with adverse maternal outcomes such as postpartum anemia. Adverse pregnancy outcomes associated with IDA include increased risk for preterm delivery and low birth weight.
Severe adverse reactions including circulatory failure (severe hypotension, shock including in the context of anaphylactic reaction) may occur in pregnant women with parenteral iron products (such as Injectafer) which may cause fetal bradycardia, especially during the second and third trimester.
You are encouraged to report Adverse Drug Events to American Regent, Inc. at 1-800-734-9236 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.